Cargando…
The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
Excision repair cross-complementing 1 (ERCC1) is reported to be involved in the sensitivity of cancer cells to platinum-based chemotherapy. The present study was designed to evaluate the effects of ERCC1 expression on the chemosensitivity of platinum agents in gastric cancer cell lines, and on survi...
Autores principales: | LIU, YONG-PING, LING, YANG, QI, QIU-FENG, ZHANG, YA-PING, ZHANG, CHANG-SONG, ZHU, CHANG-TAI, WANG, MEI-HUA, PAN, YAO-DONG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576223/ https://www.ncbi.nlm.nih.gov/pubmed/23426424 http://dx.doi.org/10.3892/ol.2012.1096 |
Ejemplares similares
-
ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015) -
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
por: Kim, Geon, et al.
Publicado: (2019) -
MACC1 decreases the chemosensitivity of gastric cancer cells to oxaliplatin by regulating FASN expression
por: Duan, Jiangman, et al.
Publicado: (2017) -
Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
por: Abyarghamsari, Mahdiye, et al.
Publicado: (2019) -
Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
por: Wang, Guoxiu, et al.
Publicado: (2018)